Option Care Health Inc

Option Care Health Inc(OPCH)股票分析

$31.210

+0.009 (+0.03%)收盤時

Loading chart…
最高
31.280
開盤
31.220
成交量加權均價
31.21
成交量
2.97M
市值
4.86B
最低
31.130
成交金額
92.60M
企業價值/稅息折舊攤銷前利潤(TTM)
13.29

Option Care Health, Inc. is an independent provider of home and alternate site infusion services. Its infusion services include the clinical management of infusion therapy, nursing support and care coordination. It provides a therapy portfolio through its network of over 87 full-service pharmacies and 109 stand-alone ambulatory infusion suites. It administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women's health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient's condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement.

AI 分析 of Option Care Health Inc (OPCH)

持有

Option Care Health Inc is currently a hold. The stock is trading at $31.20, which is very close to the acquisition price of $32.05, indicating limited upside potential. The RSI is at 93.037, suggesting the stock is overbought, which may lead to a price correction. Additionally, the forward P/E ratio is 11.22, which is attractive, but the recent downgrades from multiple analysts indicate caution. The main risk is the potential for the acquisition to face regulatory hurdles, which could impact the stock negatively if the deal does not go through.

估值指標

Option Care Health Inc(OPCH)目前預期本益比為 11.22,5 年平均預期本益比為 24.85。

預期本益比

低估
5 年均值 P/E
24.85
目前P/E
11.22
高估
31.75
低估
17.94

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
14.10
目前EV/EBITDA
13.29
高估
17.21
低估
10.99

預期股價營收比

低估
5 年均值 P/S
1.06
目前P/S
0.76
高估
1.32
低估
0.79

Alphio AI 對 OPCH 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%OPCH

$38.45

情境價格

基

基準

基準 · 50%OPCH

$31.36

情境價格

悲

悲觀

悲觀 · 25%OPCH

$30.06

情境價格

持有 OPCH 的大戶

S

Southpoint Capital Advisors LP

+ 持有OPCH

+2.04%

3個月報酬率

S

Staley Capital Advisers, Inc.

+ 持有OPCH

+1.62%

3個月報酬率

D

Durable Capital Partners, LP

+ 持有OPCH

-4.38%

3個月報酬率

事件時間軸

2026-10-07 (ET)

08:00:00

Barrington Analyst Downgrades Option Care Health to Market Perform

2026-10-06 (ET)

16:30:00

McKesson and CD&R Agree to Acquire Option Care Health for $32.05 per Share

12:30:00

Option Care Health Shares Rise 32.9% to $31.05

12:00:00

Major Averages Rise for Second Day Amid Treasury Yield Retreat

10:30:00

Option Care Health Stock Rises 32.9% to $31.05

資訊

OPCH 常見問題 —— 由 Alphio AI 解答

Option Care Health, Inc. is an independent provider of home and alternate site infusion services. Its infusion services include the clinical management of infusion therapy, nursing support and care coordination. It provides a therapy portfolio through its network of over 87 full-service pharmacies and 109 stand-alone ambulatory infusion suites. It administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women's health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient's condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement. It operates in the Healthcare sector (SERVICES-HOME HEALTH CARE SERVICES industry).

Option Care Health Inc is currently a hold. The stock is trading at $31.20, which is very close to the acquisition price of $32.05, indicating limited upside potential. The RSI is at 93.037, suggesting the stock is overbought, which may lead to a price correction. Additionally, the forward P/E ratio is 11.22, which is attractive, but the recent downgrades from multiple analysts indicate caution. The main risk is the potential for the acquisition to face regulatory hurdles, which could impact the stock negatively if the deal does not go through.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易